MC-38-CEA Cell Lines

These MC-38-CEA Cell Lines were derived from a murine colon adenocarcinoma and are engineered to express human carcinoembryonic antigen (CEA).


  • Isolated from colon carcinoma in mice
  • Express higher levels of CEA compared to other human colon carcinoma cell lines
  • MC-38-CEA-1 has similar weight to native CEA (180,000 Da)
  • MC-38 CEA-2 expressed a single (70,000 Da) glycosylated immunoreactive product

Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. In clinical use, the test measures the amount of protein that may appear in the blood of some people who have certain kinds of cancers, especially cancer of the large intestine (colon and rectal cancer). It may also be present in people with cancer of the pancreas, breast, ovary, or lung.

From the laboratories of  Jeffrey Schlom, PhD and James W. Hodge, PhD, MBA, National Cancer Institute/NIH.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
MC-38-CEA-1 Cell Line, 1 vial
1 vial In stock
Regular Price:$810.00
On Sale:
MC-38-CEA-2 Cell Line, 1 vial
1 vial In stock
Regular Price:$810.00
On Sale:

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.


Product Type: Cell Line
Name: MC-38 CEA-1, MC-38-CEA-2
Accession ID: CVCL_5I36, CVCL_5I37
Organism: Murine C57BL6
Source: Colon Carcinoma
Morphology: Epithelial
Biosafety Level: BSL2
Subculturing: 1:5, or 1:10
Growth Conditions: DMEM with 10 % FBS, 2mM glutamine, 0.1mM nonessential amino acids and 1mM sodium pyruvate and 50ug/ml gentamycin sulfate, 300 ug/ml G418, penn/strep (100x stock)
Cryopreservation: 90% FBS + 10% DMSO
Mycoplasma Tested: Yes
Storage: Liquid nitrogen
Shipped: Dry ice

From the laboratories of  Jeffrey Schlom, PhD and James W. Hodge, PhD, MBA, National Cancer Institute/NIH.
  1. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 1991 Jul 15;51(14):3657-62. PubMed PMID: 1712245.
  2. Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. 1997 Jan;20(1):38-47. PubMed PMID: 9101412.
  3. Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW. Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. J Interferon Cytokine Res. 2008 Feb;28(2):73-87. doi: 10.1089/jir.2007.0063. PubMed PMID: 18279103; PubMed Central PMCID: PMC2532849.
  4. Hand PH, Robbins PF, Salgaller ML, Poole DJ, Schlom J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother. 1993;36(2):65-75. PubMed PMID: 8425211.
  5. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 2002 Nov 15;169(10):5780-6. Erratum in: J Immunol. 2003 Mar 15;170(6):3440. PubMed PMID: 12421958.
  6. Liu Y, Wang Y, Xing J, Li Y, Liu J, Wang Z. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Des Devel Ther. 2018 Aug 29;12:2645-2654. View Article
  7. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K. Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer. Sci Rep. 2021 Mar 24;11(1):6731.  View Article 

If you publish research with this product, please let us know so we can cite your paper.